Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACT-20-CM
- Development stage
- Phase 2
- Lead developer
- Aspire Health Science
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ACT-20-CM is a cell therapy product under development for the treatment of moderate to severe COVID-19 pneumonia. It is administered intravenously and utilizes stem cell therapy as its primary mechanism of action. The product has been evaluated in clinical trials, including a Phase 2 study, but has not received regulatory approval in any country. There are no known adverse events reported to date. The developer and main company associated with this drug is Aspire Health Science[1][2].
- Brand names
- ACT-20-CMACT20-CMACT 20-CM
- Other names
- ACT-20-CMACT20-CMACT 20-CM
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)IGF-1R (Insulin-like growth factor 1 receptor)MET (Mesenchymal-epithelial transition factor receptor)VEGFR (VEGFR family)
Beyond the preview
Go deeper on ACT-20-CM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACT-20-CM.